T he nanotoxicology of the biomaterials and their derivatives is an important consideration before their clinical application as drug delivery nanocarriers.

Cardiovascular Diseases (CVDs) encompass any medical conditions related to the heart and blood vessels. Majority of CVD conditions are caused by plaque buildup in the walls of the arteries. T his condition is referred to as atherosclerosis.

Cancer is a severe disease and growing as the leading cause of disease induced death. It leads to 8.2 million death in 2012 and got 14.2 million cases. This is an enormous burden to the patients, their families and the whole society.

Imiquimod [1-(2-methylpropyl)-1H-imidazo [4,5-c] quinolin-4 amine] is imidazoquinolineamine

Excessive proliferation of cancer cells could be inhibited by disruption of microtubule network. Paclitaxel (PTX), a well-known chemotherapeutics, stabilizes microtubule networks and consequently interferes cell division. As other chemotherapeutics, pharmacodynamics of PTX seems to be promising

For a living being, both the aspects are there, the beneficial as well as the harmful effects on environment, on its living suroundings and on other associated living beings. In spite of beneficial, there are several pathogenic microorganisms (bacteria, fungi, viruses, protozoa and others), which are responsible for deadly diseases for example AIDS, diarrhea, tuberculosis, measles, immonocompromised diseases and many more. One more major threat is, trends of microorganisms, becoming resistant towards available drugs is a concern of mortallity and morbidity.

Despite tremendous advances in the diagnosis and management of Human Immunodeficiency Virus (HIV) infection in the present era of basic and clinical infectious diseases research, the constantly high mortality rate of the patients remains a challenge for scientists.

Many chronic disorders are often managed with diverse pharmacological agents or fixed dose combination due to the complementary mechanism of the drugs which have additive or synergistic effects. In the face of different co-morbidities, combination therapy with two or more agents often adequately control the multifactorial risk factors associated with such diseases. Multidrug therapy also permits lower doses of each agent to be utilized and attenuates the side effects associated with higher doses in monotherapy